<DOC>
	<DOC>NCT02093000</DOC>
	<brief_summary>This is a prospective, open-label, single arm, non-interventional study will investigate the effectiveness of Avastin monotherapy for patients with lung adenocarcinoma who previously received 4 to 6 cycles of induction platinum doublet plus Avastin. The study is expected to last approximately 28 months.</brief_summary>
	<brief_title>A Study Examining Maintenance Avastin Monotherapy in Patients With Advanced Lung Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>18 years or older Patients who previously received 4 to 6 cycles of induction platinum doublet plus bevacizumab Patients who received only 1 cycle of bevacizumab maintenance treatment meet summary of product characteristics guidelines Patients who received the first cycle of maintenance bevacizumab more than 4 weeks after the postinduction tumor assessment Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>